We, therefore, performed a post hoc analysis of two SGLT2 clinical studies, Renoprotective Effects of Dapagliflozin in Type 2 Diabetes (RED) and Renohemodynamic Effects of Combined empagliflozin and LosARtan (RECOLOR) [13,14], to investigate the association between systemic exposure to the SGLT2 inhibitors dapagliflozin and empagliflozin and changes in kidney and kidney hemodynamic variables. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.